Results 11 to 20 of about 35,545 (253)
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Cardio-OncologyBackground Immune checkpoint inhibitors (ICIs) have revolutionized the prognosis of cancer. Diabetes mellitus (DM) has been shown to have a negative effect on patients treated with ICIs.
Moran Gvili Perelman +12 more
doaj +3 more sources
Harms and benefits fo sodium-glucose co-transporter 2 inhibitors [PDF]
Australian Prescriber, 2020 Sodium-glucose co-transporter 2 inhibitors are oral glucose-lowering drugs that increase the urinary excretion of glucose. In patients with type 2 diabetes and cardiovascular disease they reduce all-cause mortality, cardiac mortality, rates of hospitalisation for heart failure and the progression of renal disease There are adverse effects related to ...
Chesterman, Thomas, Thynne, Tilenka RJ
openaire +2 more sources
Sodium-glucose co-transporter 2 inhibitors beyond diabetes
Australian Prescriber, 2022 Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by reducing the reabsorption of glucose in the kidney. They are a second-line therapy for type 2 diabetes. During clinical trials it was noticed that SGLT2 inhibitors had favourable effects on cardiovascular and renal disease.
Williams, Dimity L. +2 more
openaire +5 more sources
Safety of Sodium-Glucose Co-Transporter 2 Inhibitors [PDF]
The American Journal of Cardiology, 2019 Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety profile based on data obtained from numerous clinical trials, including cardiovascular outcomes trials (CVOTs) and postmarketing pharmacovigilance reporting. Adverse events including risk of genital mycotic infection and volume depletion-related events are consistent with the
Janet B. McGill, Savitha Subramanian
openaire +3 more sources
Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity
European Journal of Pharmaceutical Sciences, 2023 Epicardial adipose tissue is a layer of adipocytes that physiologically surround the myocardium and play some physiologic roles in normal heart function. However, in pathologic conditions, the epicardial adipose tissue can present a potent cardiac risk factor that is capable of impairing heart function through several pathways, increasing the risk of ...
Habib Yaribeygi +4 more
openaire +2 more sources
Sodium glucose co-transport 2 inhibitors for gout treatment
Discoveries, 2022 Hyperuricemia remains the most prevalent cause of gout. Gout patients present with joint inflammation and uric acid crystals deposition manifesting as tophi. The association of gout with increased risk of insulin resistance, diabetes, metabolic disorders, increased cardiometabolic risk, and kidney disease is well established.
Somagutta, Manoj Kumar Reddy +9 more
openaire +2 more sources
The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure [PDF]
Cureus, 2021 Sodium-glucose co-transporter-2 (SGLT2) inhibitors have evolved over the years, based on data from several randomized, double-blinded, placebo-controlled clinical trials. Formerly used primarily for blood sugar control in patients with diabetes, they are now used to decrease the risk of hospitalization for heart failure (HF), or of death from ...
Fadiran, Olusayo, Nwabuo, Chike
openaire +2 more sources
Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection [PDF]
International Journal of Molecular Sciences, 2021 Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of insulin.
Victor Chien-Chia Wu +2 more
openaire +2 more sources
Short-Term Effect of Sodium Glucose Co – Transporter 2 Inhibitors on Routine Laboratory Examinations
Journal of Contemporary Medicine, 2022 Backgroundː In this study, we aimed to examine the effect of Sodium Glucose Cotransporter 2 inhibitors (SGLT-2i) on routine laboratory test results at 12 weeks of follow-up among type 2 diabetes mellitus (T2D) patients using empagliflozin and ...
Osman İnan, Enes Şahiner
doaj +1 more source
A model‐based meta analysis study of sodium glucose co‐transporter‐2 inhibitors
CPT: Pharmacometrics & Systems Pharmacology, 2023 Type 2 diabetes mellitus (T2DM) agent sodium‐glucose co‐transporter 2 (SGLT2) inhibitors show special benefits in reducing body weight and heart failure risks.
Xueting Yao +5 more
doaj +1 more source